Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
13 Jun 2021
Historique:
received: 27 04 2021
revised: 26 05 2021
accepted: 07 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 27 7 2021
Statut: epublish

Résumé

Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site. Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR). Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites. Binding curves were specific for the interaction with N-linked glycans upon binding with two low-affinity carbohydrate binding sites. This biologically active assembly of a domain-swapped CVN2, or monomeric CV-N, bound to HA with a maximum K

Identifiants

pubmed: 34199200
pii: molecules26123621
doi: 10.3390/molecules26123621
pmc: PMC8231982
pii:
doi:

Substances chimiques

Bacterial Proteins 0
Polysaccharides 0
Recombinant Proteins 0
Viral Envelope Proteins 0
cyanovirin N 184539-38-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Virol. 2009 Jan;83(1):98-104
pubmed: 18945777
Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17040-5
pubmed: 23027945
Nature. 1981 Jan 29;289(5796):366-73
pubmed: 7464906
Antiviral Res. 2003 Mar;58(1):47-56
pubmed: 12719006
Virology. 1994 Oct;204(1):17-26
pubmed: 7522370
Science. 2011 Aug 12;333(6044):843-50
pubmed: 21737702
Gene. 1995 Oct 16;164(1):49-53
pubmed: 7590320
Virology. 2011 Oct 10;419(1):1-9
pubmed: 21855102
Virology. 2010 May 25;401(1):18-28
pubmed: 20202662
Antimicrob Agents Chemother. 2010 Aug;54(8):3287-301
pubmed: 20498311
Nature. 2008 Jul 10;454(7201):177-82
pubmed: 18615077
Nature. 2012 Sep 27;489(7417):566-70
pubmed: 22932267
J Virol. 2010 Oct;84(20):10690-9
pubmed: 20702629
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3739-44
pubmed: 18322015
Chem Commun (Camb). 2011 Oct 7;47(37):10440-2
pubmed: 21842053
PLoS One. 2018 May 10;13(5):e0196727
pubmed: 29746492
Mol Pharmacol. 2001 May;59(5):949-54
pubmed: 11306674
J Mol Biol. 2014 Sep 9;426(18):3166-3179
pubmed: 25036289
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13372-7
pubmed: 16174734
J Virol. 1999 May;73(5):4360-71
pubmed: 10196334
Antimicrob Agents Chemother. 2003 Aug;47(8):2518-25
pubmed: 12878514
J Biol Chem. 2010 Apr 23;285(17):13057-65
pubmed: 20147291
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Antiviral Res. 2008 Dec;80(3):266-71
pubmed: 18601954
Traffic. 2019 Apr;20(4):295-300
pubmed: 30706592
Biomolecules. 2021 Mar 22;11(3):
pubmed: 33810129
J Virol. 2015 Sep;89(18):9178-88
pubmed: 26109730
J Mol Biol. 2002 Apr 19;318(1):1-8
pubmed: 12054763
Nat Struct Biol. 1998 Feb;5(2):119-23
pubmed: 9461077
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):E5143-8
pubmed: 25404330
J Biochem. 2015 Jun;157(6):539-48
pubmed: 25713409
Protein Eng Des Sel. 2006 Dec;19(12):525-35
pubmed: 17012344
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3602-7
pubmed: 8622982
Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17107-12
pubmed: 20852065
Nat Struct Biol. 1999 Jun;6(6):530-4
pubmed: 10360354
Nature. 1995 Jul 6;376(6535):92-4
pubmed: 7596443
Virol J. 2011 Jan 12;8:11
pubmed: 21223600
Viruses. 2018 Jan 05;10(1):
pubmed: 29303997
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14079-84
pubmed: 21799112
Int J Biol Macromol. 2017 Sep;102:475-496
pubmed: 28437766
Structure. 2001 Oct;9(10):931-40
pubmed: 11591348
Nat Med. 2000 Aug;6(8):886-9
pubmed: 10932225
J Mol Biol. 1999 May 7;288(3):403-12
pubmed: 10329150

Auteurs

Irene Maier (I)

Department of Environmental Health Sciences, Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA.

Robert H Schiestl (RH)

Department of Environmental Health Sciences, Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA.

Georg Kontaxis (G)

Max Perutz Laboratories, Department of Structural and Computational Biology, University of Vienna, A-1030 Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH